Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Gastroenterology and Hepatology
Volume 2019, Article ID 3960920, 26 pages
Review Article

An Update on Clinicopathological and Molecular Features of Plexiform Fibromyxoma

1Department of Medical Education, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan
2Endoscopy Center, Changhua Christian Hospital, Changhua, Taiwan
3School of Medicine, Chung Shan Medical University, Taichung, Taiwan
4Department of Surgical Pathology, Changhua Christian Hospital, Changhua, Taiwan
5Department of Pathology and Laboratory Medicine, Taichung Veterans General Hospital, Taiwan

Correspondence should be addressed to Hsu-Heng Yen; moc.liamg@neyenalb and Chih-Jung Chen; moc.liamg@6101nehcjc

Received 29 April 2019; Accepted 16 June 2019; Published 7 July 2019

Academic Editor: Maikel P. Peppelenbosch

Copyright © 2019 Hsuan-An Su et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Plexiform fibromyxoma is a rare and newly described gastric mesenchymal tumor with only 121 reported cases in the literature. Our understanding of plexiform fibromyxoma requires updating since the first case has been reported by Takahashi et al. 12 years ago. The present review summarized reported cases in the literature, and both clinical and pathological aspects of plexiform fibromyxoma were comprehensively discussed. Plexiform fibromyxoma usually causes nonspecific or bleeding signs or symptoms, and therefore clinical recognition of the disease is challenging. Plexiform fibromyxoma is of benign nature without any metastasis or recurrence reported, and more conservative surgical treatment should be considered.